Compare NBIX & GPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | GPC |
|---|---|---|
| Founded | 1992 | 1928 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Automotive Aftermarket |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.0B |
| IPO Year | 1996 | 1994 |
| Metric | NBIX | GPC |
|---|---|---|
| Price | $130.10 | $103.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 6 |
| Target Price | ★ $180.91 | $143.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 4.03% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | 1.37 |
| Revenue | $161,626,000.00 | ★ $24,300,141,000.00 |
| Revenue This Year | $24.73 | $5.36 |
| Revenue Next Year | $13.14 | $3.70 |
| P/E Ratio | ★ $27.48 | $76.77 |
| Revenue Growth | ★ 977.51 | 3.46 |
| 52 Week Low | $105.50 | $96.08 |
| 52 Week High | $160.18 | $151.57 |
| Indicator | NBIX | GPC |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 37.29 |
| Support Level | $124.62 | $102.28 |
| Resistance Level | $135.88 | $106.48 |
| Average True Range (ATR) | 3.58 | 2.97 |
| MACD | -0.13 | -0.39 |
| Stochastic Oscillator | 59.50 | 3.05 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Genuine Parts sells aftermarket automotive parts (60% of sales) and industrial products (40% of sales) in the United States and internationally. The automotive segment primarily acts as a distributor to its network of 9,800 global retail locations, of which about two-thirds are independently owned and operated. We estimate Genuine serves around 6,000 retail locations in the US operating under the Napa Auto Parts brand, with about 80% of end-market sales derived from professional customers. Its industrial segment, primarily operating under the Motion name in the United States, is a leading distributor of bearings, power transmission, and other industrial products to more than 200,000 maintenance, repair, and original equipment manufacturer customers.